BRPI0606557A2 - método de inibição do abrigo de her2, método de redução do nìvel em soro de domìnio extracelular (ecd) de her2 em mamìferos, métodos de tratamento de cáncer em mamìferos, método de redução do nìvel de p95 her2 em célula e método de diagnóstico - Google Patents
método de inibição do abrigo de her2, método de redução do nìvel em soro de domìnio extracelular (ecd) de her2 em mamìferos, métodos de tratamento de cáncer em mamìferos, método de redução do nìvel de p95 her2 em célula e método de diagnósticoInfo
- Publication number
- BRPI0606557A2 BRPI0606557A2 BRPI0606557-0A BRPI0606557A BRPI0606557A2 BR PI0606557 A2 BRPI0606557 A2 BR PI0606557A2 BR PI0606557 A BRPI0606557 A BR PI0606557A BR PI0606557 A2 BRPI0606557 A2 BR PI0606557A2
- Authority
- BR
- Brazil
- Prior art keywords
- her2
- level reduction
- reduction method
- ecd
- extracellular domain
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
Abstract
MéTODO DE INIBIçãO DO ABRIGO DE HER2, MéTODO DE REDUçãO DO NìVEL EM SORO DE DOMìNIO EXTRACELULAR (ECD) DE HER2 EM MAMìFEROS, MéTODOS DE TRATAMENTO DE CáNCER EM MAMìFEROS, MéTODO DE REDUçãO DO NìVEL DE P95 HER2 EM CéLULA E MéTODO DE DIAGNóSTICO. O presente pedido descreve o uso de antagonistas de metaloproteases de matrizes (MMPs), especialmente MMP-15, para inibir o abrigo de HER2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65134805P | 2005-02-09 | 2005-02-09 | |
PCT/US2006/004926 WO2006086730A2 (en) | 2005-02-09 | 2006-02-09 | Inhibiting her2 shedding with matrix metalloprotease antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0606557A2 true BRPI0606557A2 (pt) | 2009-06-30 |
Family
ID=36793798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0606557-0A BRPI0606557A2 (pt) | 2005-02-09 | 2006-02-09 | método de inibição do abrigo de her2, método de redução do nìvel em soro de domìnio extracelular (ecd) de her2 em mamìferos, métodos de tratamento de cáncer em mamìferos, método de redução do nìvel de p95 her2 em célula e método de diagnóstico |
Country Status (14)
Country | Link |
---|---|
US (1) | US20060177448A1 (pt) |
EP (1) | EP1846558A2 (pt) |
JP (1) | JP2008530123A (pt) |
KR (1) | KR20070100968A (pt) |
CN (1) | CN101115836A (pt) |
AU (1) | AU2006213659A1 (pt) |
BR (1) | BRPI0606557A2 (pt) |
CA (1) | CA2595395A1 (pt) |
IL (1) | IL184564A0 (pt) |
MX (1) | MX2007009566A (pt) |
NO (1) | NO20074544L (pt) |
RU (1) | RU2007133660A (pt) |
WO (1) | WO2006086730A2 (pt) |
ZA (1) | ZA200706247B (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3065983C (en) | 2007-06-22 | 2022-07-26 | The United States Of America As Represented By The Department Of Veterans Affairs | Inhibitors of ncca-atp channels for therapy |
JP2010540460A (ja) * | 2007-09-24 | 2010-12-24 | トラガラ ファーマシューティカルズ,インク. | COX‐2阻害薬と抗HER2[ErbB2]抗体の混合物又はCOX‐2阻害薬とHER2[ErbB2]受容体チロシンキナーゼ阻害薬の混合物を用いた癌の治療 |
EP2235536A4 (en) | 2007-12-20 | 2011-05-04 | Lab Corp America Holdings | HER-2 DIAGNOSTIC METHODS |
EP2326318A4 (en) | 2008-09-16 | 2012-05-23 | Univ Maryland | SUR1 HEMMER FOR THERAPEUTIC PURPOSES |
US11401344B2 (en) | 2008-12-01 | 2022-08-02 | Laboratory Corporation Of America Holdings | Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients |
CA2764386C (en) | 2008-12-01 | 2018-05-01 | Laboratory Corporation Of America Holdings | P95-her2 antibodies and uses thereof |
US8349574B2 (en) * | 2009-01-15 | 2013-01-08 | Laboratory Corporation Of America Holdings | Methods of determining patient response by measurement of Her-3 |
ES2594893T3 (es) * | 2009-12-16 | 2016-12-23 | Abbvie Biotherapeutics Inc. | Anticuerpos anti HER2 y sus usos |
US9193791B2 (en) | 2010-08-03 | 2015-11-24 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects |
WO2012075333A2 (en) * | 2010-12-02 | 2012-06-07 | Prometheus Laboratories Inc. | Her2delta16 peptides |
WO2012159115A1 (en) | 2011-05-19 | 2012-11-22 | Laboratory Corporation Of America Holdings | Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients |
WO2013059439A2 (en) * | 2011-10-21 | 2013-04-25 | Dyax Corp. | Combination therapy comprising an mmp-14 binding protein |
WO2014037316A1 (en) * | 2012-09-07 | 2014-03-13 | Université de Liège | Combination treatment of cancer |
WO2015031119A1 (en) | 2013-08-26 | 2015-03-05 | Health Research, Inc. | Method for prophylaxis and/or treatment of erbb2 positive cancers |
CN107075490A (zh) | 2014-08-20 | 2017-08-18 | 健康研究公司 | 用于预防和/或治疗erbb1阳性癌症的方法 |
CN116925231B (zh) * | 2023-09-11 | 2023-12-12 | 中国人民解放军军事科学院军事医学研究院 | 一种抗mmp19蛋白的抗体及其应用 |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4935341A (en) * | 1986-06-04 | 1990-06-19 | Whitehead Institute For Biomedical Research | Detection of point mutations in neu genes |
US7838216B1 (en) * | 1986-03-05 | 2010-11-23 | The United States Of America, As Represented By The Department Of Health And Human Services | Human gene related to but distinct from EGF receptor gene |
US5401638A (en) * | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
US4968603A (en) * | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
US5720937A (en) * | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
CA2055441C (en) * | 1989-05-19 | 2003-01-07 | Robert M. Hudziak | Her2 extracellular domain |
US5705157A (en) * | 1989-07-27 | 1998-01-06 | The Trustees Of The University Of Pennsylvania | Methods of treating cancerous cells with anti-receptor antibodies |
US6884418B1 (en) * | 1989-08-04 | 2005-04-26 | Berlex Laboratories, Inc. | Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy |
US5183884A (en) * | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
US5571894A (en) * | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
IL101943A0 (en) * | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US6800738B1 (en) * | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
AU675916B2 (en) * | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
US5939531A (en) * | 1991-07-15 | 1999-08-17 | Novartis Corp. | Recombinant antibodies specific for a growth factor receptor |
DE69228300T2 (de) * | 1991-08-22 | 1999-09-23 | Becton Dickinson And Co., Franklin Lakes | Methoden und zusammensetzungen zur krebstherapie und zur vorhersagbarkeit der reaktionen auf diese behandlung |
US7018809B1 (en) * | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
US5288477A (en) * | 1991-09-27 | 1994-02-22 | Becton, Dickinson And Company | Method for prognosticating response to cancer therapy |
US5587458A (en) * | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
DE69333807T2 (de) * | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
AU5355594A (en) * | 1992-10-09 | 1994-05-09 | Oncor, Inc. | Methods for the detection of chromosome structural abnormalities by (in situ) hybridization to fixed tissue |
US5910486A (en) * | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
US5846749A (en) * | 1994-10-12 | 1998-12-08 | The Regents Of The University Of California | Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination |
US5804396A (en) * | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
US6214388B1 (en) * | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US5783404A (en) * | 1995-04-13 | 1998-07-21 | Amgen Inc. | Methods and compositions for determining HER-2/neu expression using monoclonal antibodies |
US6410690B1 (en) * | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
AU6113396A (en) * | 1995-06-14 | 1997-01-15 | Regents Of The University Of California, The | Novel high affinity human antibodies to tumor antigens |
US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US5783186A (en) * | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
US5925519A (en) * | 1996-06-03 | 1999-07-20 | The Regents Of The University Of California | Genetic alterations associated with prostate cancer |
US5922845A (en) * | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
IL130061A (en) * | 1996-11-27 | 2001-09-13 | Genentech Inc | Affinity purification of polypeptide on protein a matrix |
AUPO573697A0 (en) * | 1997-03-20 | 1997-04-10 | Prince Henry's Institute Of Medical Research | Diagnosis of endometrial cancer |
US5994071A (en) * | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
US6358682B1 (en) * | 1998-01-26 | 2002-03-19 | Ventana Medical Systems, Inc. | Method and kit for the prognostication of breast cancer |
JP3166705B2 (ja) * | 1998-04-16 | 2001-05-14 | 松下電器産業株式会社 | 無線装置及び送信方法 |
ATE370961T1 (de) * | 1998-05-06 | 2007-09-15 | Genentech Inc | Reinigung von antikörpern durch ionenaustauschchromatographie |
US6573043B1 (en) * | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
US6541214B1 (en) * | 1998-11-13 | 2003-04-01 | Oregon Heath Science University | N-terminally truncated HER-2/neu protein as a cancer prognostic indicator |
WO2000044225A1 (en) * | 1999-01-27 | 2000-08-03 | Cornell Research Foundation, Inc. | TREATING CANCERS ASSOCIATED WITH OVEREXPRESSION OF HER-2/neu |
US6333348B1 (en) * | 1999-04-09 | 2001-12-25 | Aventis Pharma S.A. | Use of docetaxel for treating cancers |
TR200200472T2 (tr) * | 1999-08-27 | 2002-06-21 | Genentech, Inc. | Anti-Erb B2 antikorları ile tedavi için dozajlar |
US6632979B2 (en) * | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
US6767541B2 (en) * | 2000-03-20 | 2004-07-27 | The Regents Of The University Of California | HER-2/neu overexpression abrogates growth inhibitory pathways |
KR20030043955A (ko) * | 2000-09-08 | 2003-06-02 | 파마시아 이탈리아 에스.피.에이. | 화학적 예방제로서 엑스메스탄 |
AU2002223129A1 (en) * | 2000-11-20 | 2002-05-27 | Daiichi Fine Chemical Co., Ltd. | Immunoassay method for membrane-bound matrix metalloprotease |
US6582919B2 (en) * | 2001-06-11 | 2003-06-24 | Response Genetics, Inc. | Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates |
US6602670B2 (en) * | 2000-12-01 | 2003-08-05 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on ERCC1 expression |
WO2003005971A2 (en) * | 2001-07-13 | 2003-01-23 | Paratek Pharmaceuticals, Inc. | Tetracycline compounds having target therapeutic activities |
JP2005510470A (ja) * | 2001-09-28 | 2005-04-21 | エリューシス セラピューティクス,インコーポレーテッド | 二重特異性分子を用いた癌の予防、診断、および治療の方法ならびに組成物 |
DE10254214A1 (de) * | 2002-11-20 | 2004-06-09 | Beiersdorf Ag | Oligoribonukleotide zur Behandlung von degenerativen Hauterscheinungen durch RNA-Interferenz |
WO2004087042A2 (en) * | 2003-04-04 | 2004-10-14 | Yeda Research And Development Co. Ltd. | Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins |
PT1622569E (pt) * | 2003-04-24 | 2016-03-03 | Incyte Corp | Derivados de aza espiro alcanos como inibidores de metaloproteases |
EP1678167A1 (en) * | 2003-10-17 | 2006-07-12 | Incyte Corporation | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases |
-
2006
- 2006-02-09 MX MX2007009566A patent/MX2007009566A/es not_active Application Discontinuation
- 2006-02-09 EP EP06734871A patent/EP1846558A2/en not_active Withdrawn
- 2006-02-09 AU AU2006213659A patent/AU2006213659A1/en not_active Abandoned
- 2006-02-09 US US11/351,811 patent/US20060177448A1/en not_active Abandoned
- 2006-02-09 RU RU2007133660/13A patent/RU2007133660A/ru not_active Application Discontinuation
- 2006-02-09 KR KR1020077018201A patent/KR20070100968A/ko not_active Application Discontinuation
- 2006-02-09 JP JP2007555293A patent/JP2008530123A/ja active Pending
- 2006-02-09 WO PCT/US2006/004926 patent/WO2006086730A2/en active Application Filing
- 2006-02-09 CN CNA2006800044728A patent/CN101115836A/zh active Pending
- 2006-02-09 ZA ZA200706247A patent/ZA200706247B/xx unknown
- 2006-02-09 CA CA002595395A patent/CA2595395A1/en not_active Abandoned
- 2006-02-09 BR BRPI0606557-0A patent/BRPI0606557A2/pt not_active Application Discontinuation
-
2007
- 2007-07-12 IL IL184564A patent/IL184564A0/en unknown
- 2007-09-07 NO NO20074544A patent/NO20074544L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2006086730A2 (en) | 2006-08-17 |
WO2006086730A3 (en) | 2007-03-01 |
CA2595395A1 (en) | 2006-08-17 |
ZA200706247B (en) | 2008-11-26 |
IL184564A0 (en) | 2008-12-29 |
RU2007133660A (ru) | 2009-03-20 |
KR20070100968A (ko) | 2007-10-15 |
AU2006213659A1 (en) | 2006-08-17 |
CN101115836A (zh) | 2008-01-30 |
NO20074544L (no) | 2007-11-08 |
EP1846558A2 (en) | 2007-10-24 |
JP2008530123A (ja) | 2008-08-07 |
US20060177448A1 (en) | 2006-08-10 |
MX2007009566A (es) | 2009-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0606557A2 (pt) | método de inibição do abrigo de her2, método de redução do nìvel em soro de domìnio extracelular (ecd) de her2 em mamìferos, métodos de tratamento de cáncer em mamìferos, método de redução do nìvel de p95 her2 em célula e método de diagnóstico | |
BRPI0510617A (pt) | uso de expressão de il-17 para prever inflamação de pele; processos de tratamento | |
Fagot et al. | Matrix Metalloproteinase‐1 Production Observed After Solar‐Simulated Radiation Exposure is Assumed by Dermal Fibroblasts but Involves a Paracrine Activation Through Epidermal Keratinocytes¶ | |
CL2007000797A1 (es) | Composicion farmaceutica que comprende entre alrededor de 1 y 150 mg/ml de humab igf-1r, entre alrededor de 0,001 y 1% de al menos un humectante, entre alredededor de 1 y 100 mm de un tapon a un ph entre alrededor de 5 y 7; y uso para el tratamiento de cancer de mama, cancer de pulmon y de prostata | |
CL2007001665A1 (es) | Anticuerpo o fragmento del mismo con actividad neutralizante de la proteina nr 10; agente que lo comprende; y su uso para prevenir o tratar una enfermedad inflamatoria. | |
BR112012031071A2 (pt) | 8-proteínas de ligação à il-1 | |
BRPI0510716A (pt) | uso de um agente de ligação bi-especìfico, agente de ligação bi-especìfico, composição de um agente de ligação bi-especìfico, e, kit | |
GT200600112A (es) | Composiciiones de tigeciclina y metodos de preparacion | |
AR077724A1 (es) | Anticuerpos humanos de alta afinidad contra pcsk9 | |
EP2481756A3 (en) | Compositions and methods for diagnosing and treating cancer | |
ES2534303T3 (es) | Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN | |
CL2007003622A1 (es) | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. | |
BRPI0615265A8 (pt) | composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos | |
MX349787B (es) | Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido. | |
RS54655B1 (en) | DOSAGE MODE FOR USE OF CD19XCD3 Bispecific Antibody | |
NO20055211L (no) | Anti-fungale forbindelser og fremgangsmater for anvendelse | |
EA200971131A1 (ru) | Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам | |
WO2010031056A3 (en) | Methods and compositions for modulating ire1, src, and abl activity | |
MY160041A (en) | Compositions and methods for treating parasitic infections | |
BRPI0911482A2 (pt) | Uso de epotilona d no tratamento de doenças associadas a tau incluindo doenças de alzheimer | |
BR112012009521A2 (pt) | composição farmacêutica para o tratamento de câncer compreendendo tripsinogênio e/ou quimotripsinogênio e agente ativo selecionado a partir de composto de selênio, composto vanilóide e agente de redução de glicólise citoplasmática | |
TW200605872A (en) | Alcohol-metabolism enhancing composition and ingesta containing the same | |
BRPI0514074A (pt) | aperfeiçoamentos em composições em bloco para lavatório | |
UA94922C2 (ru) | Способ регулирования специфичности сигнализации тканевого фактора у млекопитающего, которое нуждается в этом, способ идентификации агента, который специфически ингибирует сигнализацию тканевого фактора | |
DK2129391T3 (da) | Diagnostisk fremgangsmåde |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |